Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood

Kitami Hayashi, Makiko Osawa, Masao Aihara, Tatsuro Izumi, Yoko Ohtsuka, Kazuhiro Haginoya, Ikuko Kato, Kenichiro Kaneko, Kenji Sugai, Takao Takahashi, Shin ichiro Hamano, Makoto Matsukura, Hisao Miura, Kimio Minagawa, Tsunekazu Yamano, Hitoshi Yamamoto, Hideo Yamanouchi, Hideto Yoshikawa

Research output: Contribution to journalArticlepeer-review

72 Citations (Scopus)


A retrospective multicenter study was conducted, designed to evaluate the efficacy and safety of midazolam for the treatment of status epilepticus. The subjects were 358 inpatients who received intravenous midazolam therapy for status epilepticus. The mean age was 48.6 ± 46.5 months. The underlying disorder was epilepsy in 195 cases, and acute symptomatic diseases in 163 (encephalitis or encephalopathy in 88 cases). Midazolam was administered as a bolus dose (0.25 ± 0.21 mg/kg), followed if necessary by continuous infusion (0.26 ± 0.25 mg/kg/hr). The bolus injection was effective in 162 (56.6%) of the 286 cases. In the end, seizure suppression was obtained in 231 cases (64.5% of the total). The effectiveness of midazolam was lower in patients in whom midazolam was initiated more than 3 hours after seizure onset, and this tendency was particularly marked in the epilepsy group. During the treatment period, 10 patients died, but none of these deaths were associated with midazolam therapy. The incidence and types of adverse events were consistent with previously reported data. The present results indicate that midazolam is highly effective for the management of status epilepticus, if used sufficiently early after seizure onset.

Original languageEnglish
Pages (from-to)366-372
Number of pages7
JournalPediatric Neurology
Issue number6
Publication statusPublished - 2007 Jun
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology


Dive into the research topics of 'Efficacy of Intravenous Midazolam for Status Epilepticus in Childhood'. Together they form a unique fingerprint.

Cite this